Gemma Salvadó
@gsalvado.bsky.social
Leader of the Neuroimaging group at @barcelonabeta & @fpmaragall /
Associate researcher at @biofinder_study, Lund University #Alzheimer #biomarkers
Associate researcher at @biofinder_study, Lund University #Alzheimer #biomarkers
🚨Postdoc position open at @BarcelonaBeta🚨
We're looking someone to work on a project at the intersection of cardiovascular and neurodegenerative research 🫀🧠
Fully funded position!!!
More details: www.imim.cat/media/upload...
Please share!
#Alzheimer's #ENDALZ
We're looking someone to work on a project at the intersection of cardiovascular and neurodegenerative research 🫀🧠
Fully funded position!!!
More details: www.imim.cat/media/upload...
Please share!
#Alzheimer's #ENDALZ
www.imim.cat
September 18, 2025 at 1:24 PM
🚨Postdoc position open at @BarcelonaBeta🚨
We're looking someone to work on a project at the intersection of cardiovascular and neurodegenerative research 🫀🧠
Fully funded position!!!
More details: www.imim.cat/media/upload...
Please share!
#Alzheimer's #ENDALZ
We're looking someone to work on a project at the intersection of cardiovascular and neurodegenerative research 🫀🧠
Fully funded position!!!
More details: www.imim.cat/media/upload...
Please share!
#Alzheimer's #ENDALZ
Happy to see this massive collaboration out covering 12 different cohorts including almost 3,000 cognitively unimpaired individuals.
Plasma p-tau217 can be used to detect preclinical Alzheimer’s, but positive predictive values increase if +ve results are confirmed with CSF or PET
Plasma p-tau217 can be used to detect preclinical Alzheimer’s, but positive predictive values increase if +ve results are confirmed with CSF or PET
🚨Paper alert🚨
New publication in JAMA Neurology led by @gsalvado.bsky.social. In a multicentric study, we examined the clinical utility to assess preclinical #Alzheimer’s disease in cognitively unimpaired individuals.
jamanetwork.com/journals/jam...
A 🧵...
New publication in JAMA Neurology led by @gsalvado.bsky.social. In a multicentric study, we examined the clinical utility to assess preclinical #Alzheimer’s disease in cognitively unimpaired individuals.
jamanetwork.com/journals/jam...
A 🧵...
Plasma P-Tau217 to Identify Preclinical AD
This cohort study evaluates the use of plasma phosphorylated tau 217 in identifying preclinical Alzheimer disease in individuals with amyloid β pathology.
jamanetwork.com
September 17, 2025 at 6:25 PM
Happy to see this massive collaboration out covering 12 different cohorts including almost 3,000 cognitively unimpaired individuals.
Plasma p-tau217 can be used to detect preclinical Alzheimer’s, but positive predictive values increase if +ve results are confirmed with CSF or PET
Plasma p-tau217 can be used to detect preclinical Alzheimer’s, but positive predictive values increase if +ve results are confirmed with CSF or PET
Excited to share our review on the latest developments in neuroimaging in #Alzheimer’s disease .
Great resource to be up to date!
Great resource to be up to date!
🔥Recent advances in #neuroimaging of #Alzheimers disease 🧠✨
dx.doi.org/10.1002/alz....
➡️ Valuable resource for both researchers & clinicians!
➡️ ATNIV biomarkers, staging, connectomics & more
➡️ Plus: how are sex & country represented in first/last authorship?
@istaart.bsky.social Neuroimaging PIA
dx.doi.org/10.1002/alz....
➡️ Valuable resource for both researchers & clinicians!
➡️ ATNIV biomarkers, staging, connectomics & more
➡️ Plus: how are sex & country represented in first/last authorship?
@istaart.bsky.social Neuroimaging PIA
September 11, 2025 at 4:08 PM
Excited to share our review on the latest developments in neuroimaging in #Alzheimer’s disease .
Great resource to be up to date!
Great resource to be up to date!
Reposted by Gemma Salvadó
A next-generation blood test could personalize Alzheimer's treatment by revealing disease progression—not just diagnosis.
BrightFocus Foundation grant recipient, Dr. Gemma Salvadó, helped validate this test to identify ideal candidates for anti-amyloid therapies.
🔬 Full story ⬇️
BrightFocus Foundation grant recipient, Dr. Gemma Salvadó, helped validate this test to identify ideal candidates for anti-amyloid therapies.
🔬 Full story ⬇️
New Blood Test Could Personalize Alzheimer's Treatment Like Never Before
A new Alzheimer's blood test may reveal how far the disease has progressed and identify who's most likely to benefit from anti-amyloid therapies.
www.brightfocus.org
August 29, 2025 at 1:45 AM
A next-generation blood test could personalize Alzheimer's treatment by revealing disease progression—not just diagnosis.
BrightFocus Foundation grant recipient, Dr. Gemma Salvadó, helped validate this test to identify ideal candidates for anti-amyloid therapies.
🔬 Full story ⬇️
BrightFocus Foundation grant recipient, Dr. Gemma Salvadó, helped validate this test to identify ideal candidates for anti-amyloid therapies.
🔬 Full story ⬇️
New paper published today in @nataging.nature.com !
This one took some time but it's always a pleasure working hand in hand with Laia Montoliu-Gaya and the Gothenburg team. Thanks also to the McGill group for also collaborating with TRIAD data.
A 🧵 below.
#ENDALZ
This one took some time but it's always a pleasure working hand in hand with Laia Montoliu-Gaya and the Gothenburg team. Thanks also to the McGill group for also collaborating with TRIAD data.
A 🧵 below.
#ENDALZ
🚨New publication in Nature Aging🚨
Co-led between Laia Montoliu-Gaya and @gsalvado.bsky.social.
We measured several tau peptides in blood and assess their different relationships with Alzheimer’s disease stages.
nature.com/articles/s43...
🧵
Co-led between Laia Montoliu-Gaya and @gsalvado.bsky.social.
We measured several tau peptides in blood and assess their different relationships with Alzheimer’s disease stages.
nature.com/articles/s43...
🧵
Plasma tau biomarkers for biological staging of Alzheimer’s disease - Nature Aging
Montoliu-Gaya, Salvadó et al. develop a blood-based model using tau biomarkers measured in a single analysis enabling biological staging of Alzheimer’s disease to support the diagnosis, prognosis and ...
nature.com
August 23, 2025 at 10:07 AM
New paper published today in @nataging.nature.com !
This one took some time but it's always a pleasure working hand in hand with Laia Montoliu-Gaya and the Gothenburg team. Thanks also to the McGill group for also collaborating with TRIAD data.
A 🧵 below.
#ENDALZ
This one took some time but it's always a pleasure working hand in hand with Laia Montoliu-Gaya and the Gothenburg team. Thanks also to the McGill group for also collaborating with TRIAD data.
A 🧵 below.
#ENDALZ
Super proud of @noellewarmenhoven.bsky.social !
She just nailed her first oral presentation at an international conference #AAIC2025🇨🇦
She just nailed her first oral presentation at an international conference #AAIC2025🇨🇦
July 30, 2025 at 6:39 PM
Super proud of @noellewarmenhoven.bsky.social !
She just nailed her first oral presentation at an international conference #AAIC2025🇨🇦
She just nailed her first oral presentation at an international conference #AAIC2025🇨🇦
Today I will present our work titled: Biological staging of AD with the novel plasma eMTBR-tau243 and %p-tau217
🪧Insights into disease trajectory and biological staging of AD (session)
🕑 2PM
📍 Room 105 (even if it's not in the app)
Don't miss it, it will be a great session!
#AAIC2025
🪧Insights into disease trajectory and biological staging of AD (session)
🕑 2PM
📍 Room 105 (even if it's not in the app)
Don't miss it, it will be a great session!
#AAIC2025
July 28, 2025 at 1:18 PM
Today I will present our work titled: Biological staging of AD with the novel plasma eMTBR-tau243 and %p-tau217
🪧Insights into disease trajectory and biological staging of AD (session)
🕑 2PM
📍 Room 105 (even if it's not in the app)
Don't miss it, it will be a great session!
#AAIC2025
🪧Insights into disease trajectory and biological staging of AD (session)
🕑 2PM
📍 Room 105 (even if it's not in the app)
Don't miss it, it will be a great session!
#AAIC2025
Outstanding plenary presentation by @sylviavilleneuve.bsky.social today on preclinical #Alzheimer’s disease. Her comprehensive overview of biomarkers, risk factors, and clinical trials highlighted critical directions for the future of AD research.
#AAIC2025
#AAIC2025
July 27, 2025 at 6:40 PM
Outstanding plenary presentation by @sylviavilleneuve.bsky.social today on preclinical #Alzheimer’s disease. Her comprehensive overview of biomarkers, risk factors, and clinical trials highlighted critical directions for the future of AD research.
#AAIC2025
#AAIC2025
Powerful words from Cliff Jack as he accepted his lifetime achievement award.
We must protect and carry forward our longitudinal cohorts as they are the key to unlocking the mysteries of #Alzheimer’s.
#AAIC2025
We must protect and carry forward our longitudinal cohorts as they are the key to unlocking the mysteries of #Alzheimer’s.
#AAIC2025
July 27, 2025 at 4:06 PM
Powerful words from Cliff Jack as he accepted his lifetime achievement award.
We must protect and carry forward our longitudinal cohorts as they are the key to unlocking the mysteries of #Alzheimer’s.
#AAIC2025
We must protect and carry forward our longitudinal cohorts as they are the key to unlocking the mysteries of #Alzheimer’s.
#AAIC2025
If you're at #AAIC2025, don't miss the great work by @wiesjepelkmans.bsky.social !
Excited to be back at #AAIC2025! We already had a great start with an inspiring Imaging day yesterday. On Monday, I’ll present our work on how #microglial reactivity influences very early #amyloid accumulation on #PET. Come by poster 364 if you’d like to know more!
July 27, 2025 at 3:28 PM
If you're at #AAIC2025, don't miss the great work by @wiesjepelkmans.bsky.social !
What a plenary!
Congratulations @emmacoomans.bsky.social for such a great presentation at #AIC today, summarising the main neuroimaging papers of the year.
Very exciting way to start #AAIC2025 🇨🇦
Congratulations @emmacoomans.bsky.social for such a great presentation at #AIC today, summarising the main neuroimaging papers of the year.
Very exciting way to start #AAIC2025 🇨🇦
July 26, 2025 at 12:47 PM
What a plenary!
Congratulations @emmacoomans.bsky.social for such a great presentation at #AIC today, summarising the main neuroimaging papers of the year.
Very exciting way to start #AAIC2025 🇨🇦
Congratulations @emmacoomans.bsky.social for such a great presentation at #AIC today, summarising the main neuroimaging papers of the year.
Very exciting way to start #AAIC2025 🇨🇦
🚨 Heading to @EANM_NucMed meeting in Barcelona this fall?
Don’t miss our special session on the future of PET imaging in the era of emerging Alzheimer’s disease treatments.
Join the discussion on what’s next and why it matters
#EANM2025 #Neuroimaging #Alzheimers
Don’t miss our special session on the future of PET imaging in the era of emerging Alzheimer’s disease treatments.
Join the discussion on what’s next and why it matters
#EANM2025 #Neuroimaging #Alzheimers
We have a date on October 7!🧠
We are organising the event "Clinical Use of PET in Alzheimer's Disease: Challenges & Opportunities"
We'll bring together experts in the field of nuclear medicine and #Alzheimer's to explore the latest developments in PET imaging techniques.
We are organising the event "Clinical Use of PET in Alzheimer's Disease: Challenges & Opportunities"
We'll bring together experts in the field of nuclear medicine and #Alzheimer's to explore the latest developments in PET imaging techniques.
July 9, 2025 at 12:35 PM
🚨 Heading to @EANM_NucMed meeting in Barcelona this fall?
Don’t miss our special session on the future of PET imaging in the era of emerging Alzheimer’s disease treatments.
Join the discussion on what’s next and why it matters
#EANM2025 #Neuroimaging #Alzheimers
Don’t miss our special session on the future of PET imaging in the era of emerging Alzheimer’s disease treatments.
Join the discussion on what’s next and why it matters
#EANM2025 #Neuroimaging #Alzheimers
Yesterday, @anikawuestefeld.bsky.social brilliantly defended her PhD thesis on the fole of MTL in Alzheimer’s disease.
It was a brilliant discussion with @jmschott.bsky.social between peers.
Congratulations Dr. Wuestefeld! You did a great job👏👏👏
It was a brilliant discussion with @jmschott.bsky.social between peers.
Congratulations Dr. Wuestefeld! You did a great job👏👏👏
June 21, 2025 at 6:34 AM
Yesterday, @anikawuestefeld.bsky.social brilliantly defended her PhD thesis on the fole of MTL in Alzheimer’s disease.
It was a brilliant discussion with @jmschott.bsky.social between peers.
Congratulations Dr. Wuestefeld! You did a great job👏👏👏
It was a brilliant discussion with @jmschott.bsky.social between peers.
Congratulations Dr. Wuestefeld! You did a great job👏👏👏
Reposted by Gemma Salvadó
🚨New paper in Alzheimer's & Dementia! We investigate whether p-tau immuno-assays selectively quantifying low-molecular-weight (LMW) tau (CNS) are more specific for tau changes in AD vs ALS than assays not differentiating between LMW and high-MW (PNS) tau👇https://pubmed.ncbi.nlm.nih.gov/40289884/
May 5, 2025 at 12:31 PM
🚨New paper in Alzheimer's & Dementia! We investigate whether p-tau immuno-assays selectively quantifying low-molecular-weight (LMW) tau (CNS) are more specific for tau changes in AD vs ALS than assays not differentiating between LMW and high-MW (PNS) tau👇https://pubmed.ncbi.nlm.nih.gov/40289884/
Reposted by Gemma Salvadó
Super excited to announce a PhD position on polypathology in the medial temporal lobe at the Paris Brain Institute together with @nvillain-alz.bsky.social and @robindeflores.bsky.social!
offres.institutducerveau-icm.org/fr/jobs/1935...
Please repost!
offres.institutducerveau-icm.org/fr/jobs/1935...
Please repost!
Nos super offres || PhD - polypathology in the medial temporal lobe
offres.institutducerveau-icm.org
April 23, 2025 at 7:16 AM
Super excited to announce a PhD position on polypathology in the medial temporal lobe at the Paris Brain Institute together with @nvillain-alz.bsky.social and @robindeflores.bsky.social!
offres.institutducerveau-icm.org/fr/jobs/1935...
Please repost!
offres.institutducerveau-icm.org/fr/jobs/1935...
Please repost!
Important work from @biofinder.bsky.social and @barcelonabeta.bsky.social groups!
New manuscript alert! Can blood-based biomarkers measured on a fully automated platform accurately identify Alzheimer’s disease (AD) pathology?🩸 Our new multi-cohort study has now been published in
@naturemedicine.bsky.social: nature.com/articles/s41.... A thread🧵
@naturemedicine.bsky.social: nature.com/articles/s41.... A thread🧵
Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform - Nature Medicine
Among 1,767 patients in 5 centers, a fully automated blood test showed high accuracy for Alzheimer’s pathology in secondary and primary care using a predefined cutoff.
nature.com
April 9, 2025 at 4:36 PM
Important work from @biofinder.bsky.social and @barcelonabeta.bsky.social groups!
Reposted by Gemma Salvadó
🔵🔬El alzheimer ya se puede diagnosticar precozmente con un análisis de sangre. El test ya está a punto para utilizarse de manera rutinaria en los hospitales, y no solo con fines de investigación como hasta ahora.
www.lavanguardia.com/ciencia/2025...
www.lavanguardia.com/ciencia/2025...
El alzheimer ya se puede diagnosticar precozmente con un análisis de sangre
Un análisis de sangre permite diagnosticar la mayoría de casos de alzheimer de manera precoz, cuando los afectados tienen síntomas incipientes de deterioro cognitivo,
www.lavanguardia.com
April 9, 2025 at 9:30 AM
🔵🔬El alzheimer ya se puede diagnosticar precozmente con un análisis de sangre. El test ya está a punto para utilizarse de manera rutinaria en los hospitales, y no solo con fines de investigación como hasta ahora.
www.lavanguardia.com/ciencia/2025...
www.lavanguardia.com/ciencia/2025...
Huge development towards a precise and scalable diagnosis of #Alzheimer's disease.
Plasma MTBR-tau243 is more strongly associated with aggregated tau pathology and cognitive function than 🩸 p-tau217. Suggesting similar results than tau-PET with significantly lower costs and burden for patients
Plasma MTBR-tau243 is more strongly associated with aggregated tau pathology and cognitive function than 🩸 p-tau217. Suggesting similar results than tau-PET with significantly lower costs and burden for patients
‼️New publication on a novel plasma biomarker for tau pathology 🧠🧪 in @naturemedicine.bsky.social led by Kanta Horie & @gsalvado.bsky.social:
📖 www.nature.com/articles/s41...
In this study, we investigated plasma eMTBR-tau243, which closely reflects tau tangle pathology in Alzheimer’s disease (AD).
📖 www.nature.com/articles/s41...
In this study, we investigated plasma eMTBR-tau243, which closely reflects tau tangle pathology in Alzheimer’s disease (AD).
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease - Nature Medicine
Plasma eMTBR-tau243 is a specific biomarker of tau tangles in Alzheimer’s disease and enables the detecting and tracking of Alzheimer’s clinical impairment.
www.nature.com
April 1, 2025 at 11:59 AM
Huge development towards a precise and scalable diagnosis of #Alzheimer's disease.
Plasma MTBR-tau243 is more strongly associated with aggregated tau pathology and cognitive function than 🩸 p-tau217. Suggesting similar results than tau-PET with significantly lower costs and burden for patients
Plasma MTBR-tau243 is more strongly associated with aggregated tau pathology and cognitive function than 🩸 p-tau217. Suggesting similar results than tau-PET with significantly lower costs and burden for patients
Reposted by Gemma Salvadó
🚨New paper published in @alzdemjournals! doi.org/10.1002/alz.14600
PhD student Linda Karlsson et al. use machine learning (ML) to predict tau-PET composites from accessible and inexpensive modalities: plasma biomarkers, structural MRI and clinical variables. Details 👇
PhD student Linda Karlsson et al. use machine learning (ML) to predict tau-PET composites from accessible and inexpensive modalities: plasma biomarkers, structural MRI and clinical variables. Details 👇
Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data
INTRODUCTION Tau positron emission tomography (PET) is a reliable neuroimaging technique for assessing regional load of tau pathology in the brain, but its routine clinical use is limited by cost an...
doi.org
February 26, 2025 at 8:31 AM
🚨New paper published in @alzdemjournals! doi.org/10.1002/alz.14600
PhD student Linda Karlsson et al. use machine learning (ML) to predict tau-PET composites from accessible and inexpensive modalities: plasma biomarkers, structural MRI and clinical variables. Details 👇
PhD student Linda Karlsson et al. use machine learning (ML) to predict tau-PET composites from accessible and inexpensive modalities: plasma biomarkers, structural MRI and clinical variables. Details 👇
Incredible plenary presentation by @rikossenkoppele.bsky.social at AAIC Neuroscience Next in Barcelona! Ending on a hopeful note for the future of #Alzheimer's research and therapeutics.
February 25, 2025 at 2:03 PM
Incredible plenary presentation by @rikossenkoppele.bsky.social at AAIC Neuroscience Next in Barcelona! Ending on a hopeful note for the future of #Alzheimer's research and therapeutics.
Thrilled to be back home at BBRC & Fundació Pasqual Maragall as the Lead of the Neuroimaging Group! 🎉
Even better, we have a PhD position open to work with PET & MRI imaging in early stages of #Alzheimer’s. If you know someone passionate about neuroimaging, please share👇
t.co/WPPavUgpjl
Even better, we have a PhD position open to work with PET & MRI imaging in early stages of #Alzheimer’s. If you know someone passionate about neuroimaging, please share👇
t.co/WPPavUgpjl
https://www.barcelonabeta.org/es/centro-investigacion-bbrc/ofertas-empleo/phd-student-position-neuroimaging-group-barcelonabeta
t.co
February 6, 2025 at 3:36 PM
Thrilled to be back home at BBRC & Fundació Pasqual Maragall as the Lead of the Neuroimaging Group! 🎉
Even better, we have a PhD position open to work with PET & MRI imaging in early stages of #Alzheimer’s. If you know someone passionate about neuroimaging, please share👇
t.co/WPPavUgpjl
Even better, we have a PhD position open to work with PET & MRI imaging in early stages of #Alzheimer’s. If you know someone passionate about neuroimaging, please share👇
t.co/WPPavUgpjl
Reposted by Gemma Salvadó
A new The Swedish BioFINDER study paper in collaboration with WRAP has been published in
Brain!
academic.oup.com/brain/advanc...
Find our key findings 👇
Brain!
academic.oup.com/brain/advanc...
Find our key findings 👇
APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta
Cicognola et al. investigate the relationship between the APOE4 gene—the strongest genetic risk factor for Alzheimer’s disease—and tau. They find that the
academic.oup.com
January 20, 2025 at 11:51 AM
A new The Swedish BioFINDER study paper in collaboration with WRAP has been published in
Brain!
academic.oup.com/brain/advanc...
Find our key findings 👇
Brain!
academic.oup.com/brain/advanc...
Find our key findings 👇
Such an honour to receive the young investigator award from my favourite conference.
Especially when shared with these amazing researchers!
#HAI2025
I couldn't start this account with better news.
Especially when shared with these amazing researchers!
#HAI2025
I couldn't start this account with better news.
January 18, 2025 at 12:42 AM
Such an honour to receive the young investigator award from my favourite conference.
Especially when shared with these amazing researchers!
#HAI2025
I couldn't start this account with better news.
Especially when shared with these amazing researchers!
#HAI2025
I couldn't start this account with better news.